Cerdelga(eliglustat), a new drug has been approved by US FDA (Food and Drug Administration) for long treatment of adult patients with Type 1 Gaucher , a rare genetic disorder in which fatty substances (sphingolipids) accumulate in cells and certain organs due to lack of an enzyme called glucocerebrosidase.
Ceredelga , a hard gelatin capsule contains the drug Eliglustat .When administered orally it inhibits metabolic process that causes production of fatty materials .The most observed side effects of this drug observed during clinical trials process were fatigue,nausea,headache,diarrhea,abdominal pain.
Ceredelga has also recived "orphan drug "designation fro the FDA .It is manufactured by Genzyme after a Clinical development program which is the largest ever conducted in Gaucher disease,with aroud 400 patients treated in 29 countries.
Ceredelga , a hard gelatin capsule contains the drug Eliglustat .When administered orally it inhibits metabolic process that causes production of fatty materials .The most observed side effects of this drug observed during clinical trials process were fatigue,nausea,headache,diarrhea,abdominal pain.
Ceredelga has also recived "orphan drug "designation fro the FDA .It is manufactured by Genzyme after a Clinical development program which is the largest ever conducted in Gaucher disease,with aroud 400 patients treated in 29 countries.